文献速递外周动脉疾病

西罗莫司洗脱可吸收镁支架治疗膝下动脉病变的三年结果

Sirolimus-Eluting Resorbable Magnesium Scaffold for the Treatment of Patients With Infrapopliteal Arteries Disease: Three-Year Results.
PubMed 文献 · J Endovasc Ther · 2025-05-19

支架植入后残余狭窄从球囊扩张后的60.1%±15.8%降至4.8%±9.6%,36个月免于临床驱动靶病变血运重建率为87.9%,免于大截肢率为95.5%,死亡率为28.8%。作者认为该支架具有足够的力学性能、药物洗脱和吸收时间,可安全应用于膝下动脉粥样硬化病变。

要点

  • 支架植入后平均残余狭窄由球囊扩张后的60.1%±15.8%降至4.8%±9.6%。
  • 36个月免于临床驱动靶病变血运重建率为87.9%,免于大截肢率为95.5%,死亡率为28.8%。

核心结论

  • 作者认为Magmaris可吸收镁支架具有足够的力学性能、药物洗脱和吸收时间,可安全应用于膝下动脉粥样硬化病变,临床结果有前景。
  • 作者认为金属可吸收支架可能成为膝下动脉治疗现有选择的有价值补充。

研究设计与样本

  • 研究者发起的单中心回顾性研究,分析2016至2023年所有接受Magmaris可吸收镁支架治疗的症状性外周动脉闭塞性疾病患者(Rutherford症状分级2-5级)。
  • 报告技术成功、支架植入后残余狭窄程度、靶病变一期通畅率、临床驱动靶病变血运重建、大截肢和全因死亡,随访至36个月。

主要发现

  • 靶病变平均狭窄程度为92%,其中闭塞占52.2%,中重度钙化占58.5%。
  • 球囊扩张后平均残余狭窄为60.1%±15.8%,支架植入后降至4.8%±9.6%。
  • 免于临床驱动靶病变血运重建率在6、12、24、36个月分别为95.5%、93.4%、90.4%、87.9%。
  • 免于大截肢率在6、12、24、36个月分别为98.2%、98.1%、96.4%、95.5%,死亡率分别为7.6%、10.6%、24.2%、28.8%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Symptomatic infrapopliteal arterial disease often requires challenging endovascular interventions. Percutaneous transluminal angioplasty with stent placement to settle residual stenosis or dissections remains the standard of care for infrapopliteal endovascular intervention. Concerns have been raised about permanent artery rigidification by stainless steel stents. Drug-eluting resorbable scaffolds combine the mechanical support in the acute phase and the delivery of an antirestenotic drug overtime, then fully resorb leaving the vessel free from permanent metallic implant. This study investigated the performance of the Magmaris sirolimus-eluting resorbable magnesium scaffold (RMS) in the management of infra-popliteal, severely diseased leg arteries. MATERIALS AND METHODS: This investigator-initiated single-center retrospective study, analyzed all patients with symptomatic peripheral arterial occlusive disease (Rutherford class of symptoms 2-5) treated with the Magmaris RMS from 2016 to 2023, for the treatment of infrapopliteal arterial lesions with postangioplasty 50% or more residual stenosis. Technical success, degree of residual stenosis after scaffold implantation, incidences of target lesion primary patency, clinically driven target lesion revascularization (CDTLR), major limb amputation, and all-cause mortality are provided up to 36 months. RESULTS: Hundred eleven patients (69.4% male, age 79 ± 10) were treated with 141 Magmaris RMS for infrapopliteal lesions (92.3% proximal third of leg). Target lesions had a mean degree of stenosis of 92%, with 52.2% of occlusion and 58.5% of moderate or severe calcification. The mean degree of stenosis after angioplasty remained 60.1% ± 15.8% and fell to 4.8% ± 9.6% after scaffold implantation. Freedom from CDTLR was 95.5%, 93.4%, 90.4%, and 87.9% at 6, 12, 24, and 36 months. Freedom from limb major amputation was 98.2%, 98.1%, 96.4%, and 95.5% and mortality was 7.6%, 10.6%, 24.2%, and 28.8% at 6, 12, 24, and 36 months. CONCLUSION: This study suggests that the Magmaris RMS has adequate mechanical properties, drug elution, and resorption time to be safely applied to atherosclerotic infrapopliteal arteries with promising clinical results. These data show that metallic resorbable scaffold may constitute a valuable addition to current option for infrapopliteal arteries management.Clinical ImpactResorbable magnesium scaffold (RMS) are an innovation in the treatment of residual stenoses or dissections after angioplasty in the infrapopliteal arteries. They offer mechanical support and drug elution during the healing phase of the artery wall; and then disappear, leaving the artery free of any rigid implant, once the resorption is completed. RMS thus allow the restoration of artery motion and endothelial function. This study provides efficacy and safety information up to 3 years after RMS implantation in severe lesions of the leg arteries and is the largest study in the field of resorbable scaffold for below the knees arteries, as well as the first evaluating magnesium-based alloy scaffolds. It shows immediate and long-term clinical success, well beyond the entire resorption of the RMS.

来源:J Endovasc Ther,查看原文。版权归原作者所有。

引用

  1. Demierre A, Engelberger RP, Hayoz D, et al. Sirolimus-Eluting Resorbable Magnesium Scaffold for the Treatment of Patients With Infrapopliteal Arteries Disease: Three-Year Results. J Endovasc Ther. 2025. PMID: 40387638. doi:10.1177/15266028251339356

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。